Cattaneo Jennifer, De Oliveira Figueiredo Eva C, Montesel Andrea, Vermeirsch Sandra, Eandi Chiara M
Fondation Asile des Aveugles, Department of Ophthalmology, Jules-Gonin Eye Hospital, University of Lausanne, Avenue de France 15, Lausanne, 1001, Switzerland.
Moorfields Eye Hospital NHS Foundation Trust, London, UK.
Int J Retina Vitreous. 2025 Apr 8;11(1):42. doi: 10.1186/s40942-025-00665-6.
This study was conducted as a retrospective, exploratory analysis to assess early anatomical and functional effects of intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (nAMD) in a small cohort of patients.
This retrospective study was conducted at the Jules Gonin Eye Hospital in Lausanne, Switzerland, and included treatment-naïve patients with nAMD. Patients received a minimum of two intravitreal injections (IVT) of aflibercept 8 mg over a 3-month period. Key outcomes assessed were changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), mean retinal thickness (RT), total fluid (TF) volume which was calculated as the sum of intraretinal fluid (IRF), subretinal fluid (SRF) and pigment epithelial detachment (PED) volumes. These parameters were evaluated at baseline, month 1, and month 3 using the RetinAI Discovery platform, an artificial intelligence-based analysis system.
10 eyes of 10 patients were enrolled. Mean age was 77.7 ± 12.5 years. Comparative analysis between baseline, month 1, and month 3 revealed statistically significant reduction in CST, RT and TF volume, indicating a positive early response to treatment. One adverse event of intraocular inflammation (IOI) occurred in one patient (10%) after the second IVT injection. Treatment was subsequently interrupted, and IOI resolved with topical corticosteroids therapy.
Intravitreal aflibercept 8 mg demonstrated early anatomical and functional improvements in nAMD treatment-naïve patients after the first 3-months. The use of the AI-based analysis allowed for detailed and automated assessment of retinal changes, providing valuable insights into early treatment effects. Given the retrospective design and small cohort, further studies are warranted to assess long-term outcomes and the potential predictive value of early changes on long-term visual prognosis and safety.
Not applicable.
本研究作为一项回顾性探索性分析，旨在评估小队列患者中玻璃体内注射8毫克阿柏西普对新生血管性年龄相关性黄斑变性（nAMD）的早期解剖学和功能影响。
这项回顾性研究在瑞士洛桑的朱尔斯·戈宁眼科医院进行，纳入了初治nAMD患者。患者在3个月内接受至少两次玻璃体内注射（IVT）8毫克阿柏西普。评估的主要结局包括最佳矫正视力（BCVA）、中心子野厚度（CST）、平均视网膜厚度（RT）、总液体积（TF）的变化，总液体积通过视网膜内液（IRF）、视网膜下液（SRF）和色素上皮脱离（PED）体积之和计算得出。这些参数在基线、第1个月和第3个月使用RetinAI Discovery平台（一种基于人工智能的分析系统）进行评估。
纳入了10例患者的10只眼。平均年龄为77.7±12.5岁。基线、第1个月和第3个月之间的比较分析显示，CST、RT和TF体积有统计学意义的降低，表明对治疗有积极的早期反应。1例患者（10%）在第二次IVT注射后发生了1次眼内炎症（IOI）不良事件。随后中断治疗，IOI通过局部皮质类固醇治疗得到缓解。
玻璃体内注射8毫克阿柏西普在最初3个月后对初治nAMD患者显示出早期解剖学和功能改善。基于人工智能的分析的使用允许对视网膜变化进行详细和自动化评估，为早期治疗效果提供了有价值的见解。鉴于回顾性设计和小队列，有必要进行进一步研究以评估长期结局以及早期变化对长期视觉预后和安全性的潜在预测价值。
不适用。
